Cy­tori shares surge on mixed re­sults for its PhI erec­tile dys­func­tion study

Shares of San Diego-based Cy­tori Ther­a­peu­tics $CYTX bumped high­er Mon­day morn­ing on some mixed da­ta for its re­gen­er­a­tive cell ther­a­py aimed at erec­tile dys­func­tion among a small group of pa­tients with treat­ment-re­sis­tant cas­es of ED fol­low­ing rad­i­cal prosta­te­c­to­my.

There was a hit and a miss on a cou­ple of key end­points. Re­searchers say that the mi­cro­cap biotech’s ther­a­py scored a pos­i­tive p val­ue on the In­ter­na­tion­al In­dex of Erec­tile Func­tion-5 (IIEF-5), but showed no change for the Erec­tion Hard­ness Score (EHS) used by pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER